{
  "docId": "019de075-1362-766d-ac60-1333cab868aa",
  "docSlug": "7fe2865adefd4e627357f5c080658aba",
  "documentTitle": "Alkermes | Investor Presentation Deck | 56 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 56,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "testimonial",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1362-766d-ac60-1333cab868aa/14",
  "deckHref": "/decks/019de075-1362-766d-ac60-1333cab868aa",
  "deckJsonHref": "/decks/019de075-1362-766d-ac60-1333cab868aa.json",
  "deckAnchorHref": "/decks/019de075-1362-766d-ac60-1333cab868aa#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "quote",
      "text": "Outperformance has been delivered, in our view, on an attractive combination of commercial delivery, the declaration of a more focused strategy, and the emergence of a pipeline asset, ALKS 2680.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c45dde1-2d13-4148-8a27-bbae9989378c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "quote",
      "text": "We remain bullish on ALKS. We continue to believe the planned separation would unlock value for the oncology business and the standalone neuroscience company.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62a8de2b-38d1-4c22-a85f-62ee3ef165fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "quote",
      "text": "ALKS clearly has the flexibility to not only effectuate the spin-out of a funded oncology business but also execute on the addition of assets that can bolster the neuropsychiatry pipeline.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b006141-b1d8-4b97-996c-0678aa1158ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.52,
        "y": 0.55
      },
      "kind": "quote",
      "text": "ALKS put up one of its better Q's in yrs. The '23 guide was solid – LYBALVI guide was ~5% higher vs cons. & implies inflection in '23 likely on the back of DTC efforts.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab034e1e-1a71-4003-bf4e-929943c66e15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Analysts Agree: Optimism around Alkermes' Progress & Prospects",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7a942d0-c5b0-457d-976f-5ae082dfb093",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Social Proof",
      "slug": "social-proof",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "152a5248-68ee-4d78-af0a-e93e8257f74b",
      "evidence": "Analysts Agree: Optimism around Alkermes' Progress & Prospects",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "c24cfa3e-28d7-4be9-bc30-73527c8f4d2b",
      "evidence": "Use of analyst quotes to validate company strategy and performance.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "456ee3e4-026a-442c-9438-289bfd81ee8a",
      "arcName": "The Transformation Tale",
      "arcSlug": "transformation-tale",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 13-20 provide evidence of Alkermes' successful execution and growth.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}